Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jacobio Pharmaceuticals Co., Ltd.
The primary objective of this study is to evaluate the safety and tolerability of JAB-21822 monotherapy to determine the MTD and PR2D during Dose Escalation phase; then to evaluate preliminary antitumor activity when JAB-21822 administered alone and combination with cetuximab during Dose Expansion phase in adult participants with advanced solid tumors harboring KRAS G12C mutation.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must be able to provide an archived tumor sample
Histologically or cytologically confirmed solid tumors with KRAS G12C mutation
Must have received at least 1 prior standard therapy
Must have at least 1 measurable lesion per RECIST v1.1
Must have adequate organ function
Must be able to swallow and retain orally administered medication
You may not be if
Has brain or spinal metastases, except if treated and no evidence of radiographic progression or hemorrhage for at least 28 days
Active infection requiring systemic treatment within 7 days
